142 related articles for article (PubMed ID: 26743033)
1. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages.
Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T
Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033
[TBL] [Abstract][Full Text] [Related]
2. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
[TBL] [Abstract][Full Text] [Related]
3. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
[TBL] [Abstract][Full Text] [Related]
4. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.
Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S
Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788
[TBL] [Abstract][Full Text] [Related]
5. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
6. Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies.
Hristodorov D; Mladenov R; von Felbert V; Huhn M; Fischer R; Barth S; Thepen T
MAbs; 2015; 7(5):853-62. PubMed ID: 26218624
[TBL] [Abstract][Full Text] [Related]
7. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.
Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S
Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103
[TBL] [Abstract][Full Text] [Related]
8. Resolution of cutaneous inflammation after local elimination of macrophages.
Thepen T; van Vuuren AJ; Kiekens RC; Damen CA; Vooijs WC; van De Winkel JG
Nat Biotechnol; 2000 Jan; 18(1):48-51. PubMed ID: 10625390
[TBL] [Abstract][Full Text] [Related]
9. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S
Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773
[TBL] [Abstract][Full Text] [Related]
10. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin.
van Roon JA; van Vuuren AJ; Wijngaarden S; Jacobs KM; Bijlsma JW; Lafeber FP; Thepen T; van de Winkel JG
Arthritis Rheum; 2003 May; 48(5):1229-38. PubMed ID: 12746896
[TBL] [Abstract][Full Text] [Related]
11. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
12. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo.
Hristodorov D; Mladenov R; Pardo A; Pham AT; Huhn M; Fischer R; Thepen T; Barth S
Br J Cancer; 2013 Sep; 109(6):1570-8. PubMed ID: 23942071
[TBL] [Abstract][Full Text] [Related]
13. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
Hristodorov D; Amoury M; Mladenov R; Niesen J; Arens K; Berges N; Hein L; Di Fiore S; Pham AT; Huhn M; Helfrich W; Fischer R; Thepen T; Barth S
Mol Cancer Ther; 2014 Sep; 13(9):2194-202. PubMed ID: 24980949
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice.
Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED
J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein.
Goldstein J; Graziano RF; Sundarapandiyan K; Somasundaram C; Deo YM
J Immunol; 1997 Jan; 158(2):872-9. PubMed ID: 8993006
[TBL] [Abstract][Full Text] [Related]
16. Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.
Cremer C; Vierbuchen T; Hein L; Fischer R; Barth S; Nachreiner T
J Immunother; 2015 Apr; 38(3):85-95. PubMed ID: 25710248
[TBL] [Abstract][Full Text] [Related]
17. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model.
van Vuuren AJ; van Roon JA; Walraven V; Stuij I; Harmsen MC; McLaughlin PM; van de Winkel JG; Thepen T
J Immunol; 2006 May; 176(10):5833-8. PubMed ID: 16670289
[TBL] [Abstract][Full Text] [Related]
18. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
19. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.
Hristodorov D; Mladenov R; Huhn M; Barth S; Thepen T
Toxins (Basel); 2012 Sep; 4(9):676-94. PubMed ID: 23105975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]